Results 51 to 60 of about 1,520,953 (262)

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Spur-Gear-System Efficiency at Part and Full Load [PDF]

open access: yes
A simple method for predicting the part- and full-load power loss of a steel spur gearset of arbitrary geometry supported by ball bearings is described. The analysis algebraically accounts for losses due to gear sliding, rolling traction, and windage in ...
Anderson, N. E., Loewenthal, S. H.
core   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

open access: yesMolecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir   +12 more
wiley   +1 more source

Predicted and experimental performance of jet-lubricated 120-millimeter-bore ball bearings operating to 2.5 million DN [PDF]

open access: yes
Bearing inner- and outer-race temperatures and friction power losses were calculated using two computer programs. The values obtained were compared with previously reported experimental data for 120 mm bore bearings which operated at thrust loads to 22 ...
Coe, H. H., Zaretsky, E. V.
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui   +6 more
wiley   +1 more source

Weighted Proportional Losses Solution [PDF]

open access: yes
We propose and characterize a new solution for problems with asymmetric bargaining power among the agents that we named weighted proportional losses solution.
Jaume García Segarra   +1 more
core  

Designing power inductors: practical solutions [PDF]

open access: yes, 2011
An overview of losses and thermal aspects if power inductors is given. Most of the time core losses are given only for sine square wave, but users use it in square waves. Also bulk currents affect losses in larger inductors.
Van den Bossche, Alex
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy